1.0
Cite Score 2025
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 17, Issue 4 (2025)
3 2025, 17(4): 399-405 |
Back to browse issues page
Request Type:
History
Received: 2025/10/19 | Accepted: 2025/11/25 | Published: 2025/11/30
Received: 2025/10/19 | Accepted: 2025/11/25 | Published: 2025/11/30
How to cite this article
Rasheed Z, Ayyed H, Taha J. Assessment of Minimal Erythema Dose of Narrow Band Ultraviolet-B in a Sample of Iraqi Patients with Vitiligo and Psoriasis. 3 2025; 17 (4) :399-405
URL: http://ijwph.daneshafarand.org/article-3-85664-en.html
URL: http://ijwph.daneshafarand.org/article-3-85664-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Physics, Faculty of Education, Al-Iraqia University, Baghdad, Iraq
2- Department of Physiology, Faculty of Medicine, Al-Nahrain University, Baghdad, Iraq
2- Department of Physiology, Faculty of Medicine, Al-Nahrain University, Baghdad, Iraq
Abstract (627 Views)
Aims: This study aimed to determine the minimal erythema dose in a group of patients with vitiligo and psoriasis from Iraq.
Materials & Methods: This analytical cross-sectional study was conducted on 21 patients (13 females and 8 males, aged 9 to 60 years) with psoriasis and vitiligo who attended the Department of Dermatology at the Medical City Teaching Hospital, Baghdad, over a four-month period. Fifteen patients had vitiligo, while six had psoriasis. Skin type was III in 10 patients and IV in 11. A complete general, systemic, and dermatological examination was performed, including the number of depigmented macules, the site of involvement, and the approximate percentage of body surface area affected. Data were analyzed using Microsoft Office Excel 2010 with a two-tailed t-test.
Findings: The minimal erythema dose ranged from 350 to 600mJ/cm². The mean minimal erythema dose was 448.1±87.6mJ/cm². There were no statistically significant differences between males (457.50±119.13mJ/cm²) and females (442.30±66.35mJ/cm²; p=0.710). Likewise, no significant difference was observed between patients with psoriasis (430.00±84.61mJ/cm²) and those with vitiligo (455.33±90.5mJ/cm²; p=0.563). In addition, there was no significant difference between patients with skin type III (447.00±89.69mJ/cm²) and skin type IV (449.09±89.93mJ/cm²; p=0.958).
Conclusion: Gender, disease type (vitiligo or psoriasis), and skin types III and IV do not affect the minimal erythema dose.
Materials & Methods: This analytical cross-sectional study was conducted on 21 patients (13 females and 8 males, aged 9 to 60 years) with psoriasis and vitiligo who attended the Department of Dermatology at the Medical City Teaching Hospital, Baghdad, over a four-month period. Fifteen patients had vitiligo, while six had psoriasis. Skin type was III in 10 patients and IV in 11. A complete general, systemic, and dermatological examination was performed, including the number of depigmented macules, the site of involvement, and the approximate percentage of body surface area affected. Data were analyzed using Microsoft Office Excel 2010 with a two-tailed t-test.
Findings: The minimal erythema dose ranged from 350 to 600mJ/cm². The mean minimal erythema dose was 448.1±87.6mJ/cm². There were no statistically significant differences between males (457.50±119.13mJ/cm²) and females (442.30±66.35mJ/cm²; p=0.710). Likewise, no significant difference was observed between patients with psoriasis (430.00±84.61mJ/cm²) and those with vitiligo (455.33±90.5mJ/cm²; p=0.563). In addition, there was no significant difference between patients with skin type III (447.00±89.69mJ/cm²) and skin type IV (449.09±89.93mJ/cm²; p=0.958).
Conclusion: Gender, disease type (vitiligo or psoriasis), and skin types III and IV do not affect the minimal erythema dose.
References
1. Hamouda SA, Alshawish NK, Abdalla YK, Ibrahim MK. Ultraviolet radiation: Health risks and benefits. Saudi J Eng Technol. 2022;7(10):533-41. [Link] [DOI:10.36348/sjet.2022.v07i10.001]
2. Chilingar GV, Sorokhtin OG, Khilyuk LF, Haroun M, Albannay A. Absorption of the solar ultraviolet radiation by the earth's atmosphere and ozone formation. J Sustain Energy Eng. 2013;1(2):161-8. [Link] [DOI:10.7569/JSEE.2012.629509]
3. Myers E, Kheradmand S, Miller R. An update on narrowband ultraviolet B therapy for the treatment of skin diseases. Cureus. 2021;13(11):e19182. [Link] [DOI:10.7759/cureus.19182]
4. Salman KE, Altunay I, Salman A. The efficacy and safety of targeted narrowband UVB therapy: A retrospective cohort study. Turk J Med Sci. 2019;49(2):595-603. [Link] [DOI:10.3906/sag-1810-110]
5. Brenner AV, Lubin JH, Calista D, Landi MT. Instrumental measurements of skin color and skin ultraviolet light sensitivity and risk of cutaneous malignant melanoma: A case-control study in an Italian population. Am J Epidemiol. 2002;156(4):353-62. [Link] [DOI:10.1093/aje/kwf045]
6. Kaur HS, Chen JS, Doolan BJ, Gupta M. Narrow-band UVB phototherapy-Australian consensus-based recommendations. Australas J Dermatol. 2022;63(3):387-91. [Link] [DOI:10.1111/ajd.13850]
7. Huang MW, Lo PY, Cheng KS. Objective assessment of sunburn and minimal erythema doses: Comparison of noninvasive in vivo measuring techniques after UVB irradiation. EURASIP J Adv Signal Process. 2010;2010:1-7. [Link] [DOI:10.1155/2010/483562]
8. Ibbotson SH. A perspective on the use of NB-UVB phototherapy vs. PUVA photochemotherapy. Front Med. 2018;5:184. [Link] [DOI:10.3389/fmed.2018.00184]
9. Derheimer FA, Hicks JK, Paulsen MT, et al. Psoralen-induced DNA interstrand cross-links block transcription and induce p53 in an ataxia-telangiectasia and rad3-related-dependent manner. Mol Pharmacol. 2009;75:599-607. [Link] [DOI:10.1124/mol.108.051698]
10. Matos TR, Ling TC, Sheth V. Ultraviolet B radiation therapy for psoriasis: pursuing the optimal regime. Clin Dermatol. 2016;34:587-593. [Link] [DOI:10.1016/j.clindermatol.2016.05.008]
11. Vieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacol Ther. 2021;222: 107784. [Link] [DOI:10.1016/j.pharmthera.2020.107784]
12. Mai SN, Pham GP, Van Toi V, Huynh K, Pham TTH. Using UVB 311 nm narrow-band medical lamp for the treatment of psoriasis. Proceedings of the 7th International Conference on the Development of Biomedical Engineering in Vietnam (BME7) Translational Health Science and Technology for Developing Countries 7. Singapore: Springer; 2020. p. 413-9. [Link] [DOI:10.1007/978-981-13-5859-3_73]
13. Almokhtar MN. Phototesting for a variety of skin conditions before narrowband (TL-01) Ultraviolet-B. Grn Int J Apl Med Sci. 2024;2(5):182-8. [Link] [DOI:10.62046/gijams.2024.v02i05.004]
14. Lee EJ, Lee CH, Baek JH, Koh JS, Boo YC. A spectrophotometric method to determine minimal erythema dose for ultraviolet radiation in human skin. Biomedicines. 2024;12(11):1-15. [Link] [DOI:10.3390/biomedicines12112544]
15. Valbuena Mesa MC, Nova Villanueva JA, Sánchez Vanegas G. Minimal erythema dose: Correlation with Fitzpatrick skin type and concordance between methods of erythema assessment in a patient sample in Colombia. Actas Dermosifiliogr. 2020;111(5):390-7. [Link] [DOI:10.1016/j.adengl.2019.12.010]
16. Dogra S, De D. Narrowband ultraviolet B in the treatment of psoriasis: The journey so far!. Indian J Dermatol Venereol Leprol. 2010;76(6):652-61. [Link] [DOI:10.4103/0378-6323.72461]
17. Graham IH, Antony RY. Ultraviolet radiation-induced erythema in human skin. Methods. 2002; 28(1): 14. [Link] [DOI:10.1016/S1046-2023(02)00205-0]
18. Sanclemente G, Zapata JF, J.J. García, A. Gaviria, L.F. Gómez, M. Barrera. Lack of correlation between minimal erythema dose and skin phototype in a Colombian scholar population. Skin Res Technol. 2008;14:403-409. [Link] [DOI:10.1111/j.1600-0846.2008.00306.x]
19. Yang JW, Fan GB, Tan F, Kong HM, Liu Q, Zou Y, et al. The role and safety of UVA and UVB in UV-induced skin erythema. Front Med. 2023;10:1163697. [Link] [DOI:10.3389/fmed.2023.1163697]
20. Tejasvi T, Sharma VK, Kaur J. Determination of minimal erythemal dose for narrow band-ultraviolet B radiation in north Indian patients: Comparison of visual and dermaspectrometer readings. Indian J Dermatol Venereol Leprol. 2007;73(2):97-9. [Link] [DOI:10.4103/0378-6323.31893]
21. Jeon SY, Lee CY, Song KH, Kim KH. Spectrophotometric measurement of minimal erythema dose sites after narrowband ultraviolet B phototesting: Clinical implication of spetrophotometric values in phototherapy. Ann Dermatol. 2014;26(1):17-25. [Link] [DOI:10.5021/ad.2014.26.1.17]
22. Li YW, Chu CY. The minimal erythema dose of broadband ultraviolet B in Taiwanese. J Formos Med Assoc. 2007;106:975-978. [Link] [DOI:10.1016/S0929-6646(08)60071-6]
23. Pérez Ferriols A, Aguilera J, Aguilera P, de Argila D, Barnadas MA, de Cabo X, et al. Determination of minimal erythema dose and anomalous reactions to UVA radiation by skin phototype. Actas Dermosifiliogr. 2014; 105:780-788. [Link] [DOI:10.1016/j.adengl.2014.05.020]
24. Carretero-Mangolis C, Lim HW. Correlation between skin types and minimal erythema dose in narrowband UVB (TL-01) phototherapy. Photodermatol Photoimmunol Photomed. 2001;17:244-246. [Link] [DOI:10.1111/j.1600-0781.2001.170508.x]
25. Palmer RA, Aquilina S, Milligan PJ, Walker SL, Hawk JL, Young AR. Photoadaptation during narrowband ultraviolet-B therapy is independent of skin type: a study of 352 patients. J Invest Dermatol. 2006;126:1256-1263, [Link] [DOI:10.1038/sj.jid.5700287]